Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(2.10) per share which beat the analyst consensus estimate of $(3.16) by 33.54 percent. This is a 65 percent increase over losses of $(6.00) per share from the same period last year.
Related Posts
Roblox Stock Has Halved In 1 Year But This Analyst Sees Path For Continued Monetization Growth In US
Needham analyst Bernie McTernan maintained Roblox Corp (NYSE:RBLX) with a Buy and cut the price target from $55 to $53 after lower-than-expected August…
Berenberg Upgrades BP to Buy
Berenberg analyst Henry Tarr upgrades BP (NYSE:BP) from Hold to Buy.
Orbital Energy Group Reports Strategic Reorganization Of Its Solar Unit
New Structure and Accomplished Executive Team Designed to Further Accelerate Solar Division's Efficiency and Profitability
HOUSTON, April 26, 2022 /PRNewswire/ -- Orbital Energy Group, Inc. (NASDAQ:OEG)